Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 8/20 | 0.51 |
| ▸ | IDO1 | P14902 | 10/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27894604 | 0.78 | CYP2A6 (0.57) | CSNK2A1FFAR1 | |
| SCHEMBL3900981 | 0.78 | CSNK2A1 (0.70) | CSNK2A1NPC1TP53MAPTXBP1 | |
| SCHEMBL1715589 | 0.75 | AGXT (0.51) | AGXTIDO1 | |
| SCHEMBL4080073 | 0.74 | CSNK2A1 (0.49) | CSNK2A1NPC1TP53MAPTXBP1 | |
| SCHEMBL6058567 | 0.73 | ESR1 (0.50) | CSNK2A1 | |
| SCHEMBL4071488 | 0.72 | CSNK2A1 (0.46) | CSNK2A1CYP3A4HSD17B10MRGPRX4 | |
| SCHEMBL6058977 | 0.71 | GSTP1 (0.57) | CSNK2A1FFAR1NPC1TP53MAPT | |
| SCHEMBL1521149 | 0.70 | AGXT (0.73) | AGXTIDO1CYP3A4 | |
| SCHEMBL358974 | 0.70 | PRKCI (0.44) | CYP3A4SMN1; SMN2HSD17B10MRGPRX4 | |
| Hydrochloric Acid SCHEMBL14686234 | 0.69 | AGXT (0.71) | AGXTIDO1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | AGXT 4169/4885IDO1 480/4885CSNK2A1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.